Search

Your search keyword '"Kish JK"' showing total 36 results

Search Constraints

Start Over You searched for: Author "Kish JK" Remove constraint Author: "Kish JK"
36 results on '"Kish JK"'

Search Results

1. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

7. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

8. Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting.

9. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19.

10. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.

11. Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.

13. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.

14. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.

15. Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States.

16. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.

17. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.

18. Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.

19. Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer.

20. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy.

21. Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies.

22. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.

23. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.

24. Prioritizing US Cervical Cancer Prevention With Results From a Geospatial Model.

25. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.

26. Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

27. Earlier presentation and application of curative treatments in hepatocellular carcinoma.

28. Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries.

30. Ethnicity predicts metabolic syndrome after liver transplant.

31. Burden of Human Papillomavirus among Haitian Immigrants in Miami, Florida: Community-Based Participatory Research in Action.

32. The BEACHES Study: health effects and exposures from non-point source microbial contaminants in subtropical recreational marine waters.

33. An evaluation of health communication materials for individuals with disabilities developed by three state disability and health programs.

34. Preventing heat-related morbidity and mortality: new approaches in a changing climate.

35. Oncocytic adenocarcinoma of minor salivary gland. An unusual glossal presentation of a minor salivary gland tumor.

36. Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites.

Catalog

Books, media, physical & digital resources